1 / 66

Early Identification of Cognitive Disorders: Impact on Diagnosis and Treatment

Early Identification of Cognitive Disorders: Impact on Diagnosis and Treatment. Ohio State University Douglas W. Scharre, MD. Douglas W. Scharre, MD Disclosures. Research Support National Institutes of Health - NIA Alzheimer’s Disease Cooperative Study

oren
Download Presentation

Early Identification of Cognitive Disorders: Impact on Diagnosis and Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Early Identification of Cognitive Disorders: Impact on Diagnosis and Treatment Ohio State University Douglas W. Scharre, MD

  2. Douglas W. Scharre, MD Disclosures • Research Support • National Institutes of Health - NIA • Alzheimer’s Disease Cooperative Study • Eisai, Elan, Wyeth, Eli Lily, GalxoSmithKline, Bristol Meyers Squibb, Sonexa, Wyeth • Speakers Bureau • Eisai, Novartis, Forest • Consultant • GalaskoSmithKline Objective: Review early identification techniques for cognitive disorders. Review cognitive assessment instruments for MCI and early dementia. Discuss the impact on diagnosis and treatment. I own no stocks or equity in any pharmaceutical company

  3. Prevalence of Dementia Increases with Age Evans, et al. JAMA 1989;262:2551-2556

  4. 2000 2010 2020 2030 2040 2050 Projected Prevalence of AD 4.5 Million AD Cases Today—Over 14 Million Projected Within a Generation 16 14.3 14 11.3 12 10 8.7 Millions 8 6.8 5.8 6 4 4 2 0 Year Evans DA et al. Milbank Quarterly. 1990;68:267-289.

  5. Definitions

  6. Normal Mild Cognitive Impairment Dementia

  7. Dementia Definition • Syndrome of acquired persistent intellectual impairment • Persistent deficits in at least three of the following: memory language visuospatial personality or emotional state cognition • Resulting in impairment in Activities of Daily Living (ADL)

  8. Mild Cognitive Impairment (MCI) Definition • Memory complaint usually corroborated by an informant • Objective memory impairment for age - that represents a change in function for the person • Essentially preserved general cognitive function • Largely intact functional activities • Not demented • Alzheimer’s disease may start like this but many non-AD conditions present like this also Petersen J Int Med 2004;256;183-194

  9. MCI: Rates of Dementia Conversion • Vary from 1% - 25% per year to AD depending on the definition used and measurement instruments • 10% - 12% per year to AD is typical • 57% conversion to dementia after 3 years in one study • 25% do not convert to dementia even with long term follow-up Chertkow et al. Neurology 2001;56:B46

  10. Methods of Screening

  11. Screening with Biomarkers

  12. Biomarkers in AD • Cerebrospinal fluid (CSF) biomarkers • Tau ( in CSF in AD) • A42 ( in CSF in AD) • Neural thread protein (NTP) • Homocysteine ( level,  risk of AD) • Isoprostanes (oxidative/nitrative damage -  levels in blood and CSF in AD) • Sulfatide (in CSF in AD) • Blood and urine biomarkers • Genetic blood tests and genotyping • Plasma A42, Homocysteine, isoprostanes, sulfatide • Urine neural thread protein (NTP)

  13. Motter et al. Ann Neurol 1995;38:643-48

  14. Screening with Neuroimaging

  15. Early Diagnosis: Structural Neuroimaging • Volumetric measurement of hippocampus and entorhinal cortex atrophy with MRI is sensitive (95%) but not specific (40%) for AD • Change in MRI hippocampal volume may be predictive over time in both MCI and individuals at genetic risk for AD • 7-Tesla and 8-Tesla MRI being used in AD research Laakso et al. Neurology 1996;46:678-81 Golomb et al. Neurology 1996;47:810-3 Whitaker et al. Society for Neuroscience 2001

  16. Gray Matter Reductions in AD Using Voxel Based Morphometry Alexander GE et al., ADNI MRI Core Team, 2007

  17. Functional Neuroimaging: PET • PET shows hypometabolism in bilateral parietal, temporal, and posterior cingulate cortex in AD subjects and those who are asymptomatic but at increased risk for AD (those with Apo E 4) • PET predicted 94% of mild cognitive impairment (MCI) subjects whose disease progressed to dementia during a 3 year period Minoshima et al. J Nucl Med 1995;36:1238-48 Minoshima et al. Ann Neurol 1997;42:85-94 Small et al. JAMA 1995;273:942-47

  18. Typical AD PET Scan Normal Brain AD Brain Provided courtesy of M. Mega, MD, PhD, Department of Neurology, UCLA School of Medicine.

  19. Preliminary FDG PET Comparisons: Regional Hypometabolism in Probable AD (purple) & MCI (blue) Chen, K, et al., ADNI PET Coordinating Center, 2007

  20. PET with Pittsburgh Compound B (PIB) • PIB is a hydroxylated benzothiozole PET tracer • Attaches to the amyloid beta peptide • MCI patients have more amyloid than normals and less that AD patients Klunk et al. Ann Neurol 2004;55(1)

  21. Cognitive Screening

  22. 5 4 3 Patients (millions) 2 1 0 Prevalence Diagnosed Treated* Treatment of Alzheimer’s Disease * Any drug treatment, not limited to acetylcholinesterase inhibitors. Source: Decision Resources, March 2000.

  23. Barriers to Early Diagnosis of MCI and Dementia • Patients with MCI and early dementia have impaired insight • First present to the doctor an average of 3.5 years after cognitive symptoms start • Physicians may not notice subtle cognitive deficits in routine office visits • Little reimbursement for cognitive screens • Often too much time or personnel resources required to administer testing Barker WW et al. Alzheimer Dis Assoc Disord2005;19:1-7

  24. Examples of Brief Cognitive Assessment/Screening Tests • MMSE • Clock Drawing Test • Mini-Cog • AD8 • 7-minute Screen • Montreal Cognitive Assessment (MoCA) • Self-Administered Gerocognitive Examination (SAGE)

  25. MMSE • Score: 0 (worst) - 30 (best) • Tests orientation, attention, mental control, calculations, delayed memory (no clueing), language, and constructional praxis • Easy to use, well known • Not great for frontal or executive functions • Sensitivity 78% and specificity 84% for dementia with a cutoff of 26/30 • Takes 7 to 10 minutes; needs examiner • PAR bought rights - costs about $1 per use Folstein et al. J Psychiat Res 1975;12:189-98 Feher et al. Arch Neurol 1992;49:87-92

  26. MMSE Folstein et al. J Psychiat Res 1975;12: 189-98

  27. Mini-Mental State Examination:Typical change over time Mild Cognitive Impairment (MCI)

  28. Clock Drawing Test • Various scoring methods • Tests constructional praxis, visuospatial skills, and executive functioning • Easy to use, well known • Limited in evaluating other cognitive domains • Sensitivity 83% and specificity 72% for AD • Takes 1 minute; needs no examiner Shulman et al. Int Geriatr Psychiatry 1986;1:135-40 Cahn et al. Arch Clin Neuropsych 1996;11:529-39

  29. Early Diagnis: Cognitive Screening

  30. Mini-Cog • 3-item recall and clock drawing • Easy to use • Limited in evaluating other cognitive domains • Sensitivity 76% and specificity of 89% for dementia • Score not influenced by language or education • Takes 3 minutes; needs examiner Borson S et al. Int J Geriatr Psychiatry 2000;15:1021-1027 Borson S et al. JAGS 2003;51:1451-1454

  31. Mini-Cog

  32. AD8 • Score: 0 (best) - 8 (worst) • Informant rates changes in the patient’s judgment, interests, memory, functioning, and orientation • Easy to use • Does not measure patient cognition • Sensitivity 84% and specificity 80% for dementia with a cutoff of 2 or greater • Takes 3 minutes; needs examiner and informant Folstein et al. J Psychiat Res 1975;12:189-98 Feher et al. Arch Neurol 1992;49:87-92

  33. AD8 Galvin et al. Neurology 2006;67:1942-1948

  34. 7 Minute Screen • Special scoring calculator required • Tests orientation, memory, clock drawing, verbal fluency • Not easy to use in primary care office • Low scores very specific for AD • Sensitivity 92% and specificity 96% for AD vs normal controls • Takes 7 - 12 minutes; needs examiner Solomon et al. Arch Neurol 1998;55:349-55

  35. 7 Minute Screen

  36. Montreal Cognitive Assessment (MOCA) • Score: 0 (worst) - 30 (best) • Tests orientation, memory, clock drawing, constructions, verbal fluency, naming, repetition, attention, abstraction, calculations, executive (trails B) • Not easy to give in primary care office • Sensitivity 100% and specificity 87% for AD vs normal controls with a cutoff of 26/30 • Takes 10-13 minutes; needs examiner Nasreddine et al. J Am Geriatr Soc 2005;53:695-699

  37. MOCA Nasreddine et al. J Am Geriatr Soc 2005;53:695-699

  38. Self-Administered Gerocognitive Exam (SAGE) • Score: 0 (worst) - 22 (best) • Tests orientation, memory, language, fluency, naming, visuospatial, abstraction, calculations, executive functioning, and problem solving • Self-administered, easy to use • Limited memory evaluation; excellent executive measures • Takes 10 to 15 minutes; needs no examiner Scharre et al. Alzheimer Dis Assoc Disord 2009 at sagetest.osu.edu

  39. SAGEPage 1 Scharre et al. Alzheimer Dis Assoc Disord 2009 at sagetest.osu.edu

  40. SAGEPage 2 Scharre et al. Alzheimer Dis Assoc Disord 2009 at sagetest.osu.edu

  41. SAGEPage 3 Scharre et al. Alzheimer Dis Assoc Disord 2009 at sagetest.osu.edu

  42. SAGEPage 4 Scharre et al. Alzheimer Dis Assoc Disord 2009 at sagetest.osu.edu

  43. SAGE: Validity Against Neuropsychologic Tests Scharre et al. Alzheimer Dis Assoc Disord 2009

  44. SAGE Validity Study • Correlation between SAGE & neuropsychology battery was 0.84 (0.76 for MMSE) • Cognitive impaired group = MCI + dementia • ROC analysis for SAGE, normal vs cognitive impaired: sensitivity is 95% (90% for MMSE) and specificity is 79% (71% for MMSE) with a cut off score of 17/22 Scharre et al. Alzheimer Dis Assoc Disord 2009 at sagetest.osu.edu

  45. ROC for SAGE: Differentiating normal vs MCI + Dementia Scharre et al. Alzheimer Dis Assoc Disord 2009 at sagetest.osu.edu

  46. Self-Administered Gerocognitive Exam (SAGE) • Validity against neuropsychological tests: r = 0.85 • Inter-rater reliability: correlation coefficient = 0.96 • Test-retest reliability: correlation coefficient = 0.86 • Age, gender, and version of SAGE (4 different forms available) had no effect on SAGE score • Education had a moderate effect on SAGE score (p = 0.025) only in those less than 12 years of schooling Scharre et al. Alzheimer Dis Assoc Disord 2009 at sagetest.osu.edu

  47. SAGE Scores 17-22: Very likely to be normal - no further evaluation 15-16: Likely to have MCI - staged screening evaluation recommended 0-14: Likely to have a dementia condition - staged screening evaluation recommended

  48. Staged Screening: Impact of Diagnosis

More Related